Similar articles for PMID: 11117982

Year	Number of Results
1979	1
1980	2
1983	2
1985	2
1987	1
1990	1
1996	1
1997	2
1998	4
1999	2
2000	15
2001	11
2002	9
2003	16
2004	13
2005	6
2006	5
2007	3
2008	1
2010	2
2011	1
2012	1
2016	1
2020	1
2022	1
2024	0

1

The FDA, regulation, and the risk of stroke.

Fleming GA. Fleming GA. N Engl J Med. 2000 Dec 21;343(25):1886-7. doi: 10.1056/NEJM200012213432510. N Engl J Med. 2000. PMID: 11117982 No abstract available.

2

Phenylpropanolamine and hemorrhagic stroke.

Ernst ME, Hartz A. Ernst ME, et al. N Engl J Med. 2001 Apr 5;344(14):1094; author reply 1095. N Engl J Med. 2001. PMID: 11291667 No abstract available.

3

Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.

Haller CA, Benowitz NL. Haller CA, et al. N Engl J Med. 2000 Dec 21;343(25):1833-8. doi: 10.1056/NEJM200012213432502. N Engl J Med. 2000. PMID: 11117974 Free article.

4

Phenylpropanolamine and hemorrhagic stroke in the Hemorrhagic Stroke Project: a reappraisal in the context of science, the Food and Drug Administration, and the law.

Stier BG, Hennekens CH. Stier BG, et al. Ann Epidemiol. 2006 Jan;16(1):49-52. doi: 10.1016/j.annepidem.2005.01.012. Epub 2005 Oct 10. Ann Epidemiol. 2006. PMID: 16216529

5

FDA issues public health advisory on phenylpropanolamine in drug products.

Meadows M. Meadows M. FDA Consum. 2001 Jan-Feb;35(1):9. FDA Consum. 2001. PMID: 11930934 Free article. No abstract available.

6

Phenylpropanolamine and stroke: the study, the FDA ruling, the implications.

Mersfelder TL. Mersfelder TL. Cleve Clin J Med. 2001 Mar;68(3):208-9, 213-9, 223. doi: 10.3949/ccjm.68.3.208. Cleve Clin J Med. 2001. PMID: 11263849 Free article. Review.

7

Phenylpropanolamine and hemorrhagic stroke.

Wolowich WR, Casavant MJ, Ekins BR. Wolowich WR, et al. N Engl J Med. 2001 Apr 5;344(14):1094-5. doi: 10.1056/NEJM200104053441411. N Engl J Med. 2001. PMID: 11291666 No abstract available.

8

[Stroke and phenylpropanolamine: what risk factors and what recommendations in request?].

Die-Kacou H, Kamagaté M, Daubrey-Potey TH, Bamba-Kamagaté D, Yavo JC, Balayssac E, Gboignon VM, Kakou KA, Gilbernaire AF. Die-Kacou H, et al. Dakar Med. 2007;52(1):56-7. Dakar Med. 2007. PMID: 19102094 French. No abstract available.

9

Regulatory decisions in a globalised world: the domino effect of phenylpropanolamine withdrawal in Latin America.

Figueras A, Laporte JR. Figueras A, et al. Drug Saf. 2002;25(10):689-93. doi: 10.2165/00002018-200225100-00001. Drug Saf. 2002. PMID: 12167064

10

Regarding "Phenylpropanolamine and hemorrhagic stroke in the hemorrhagic stroke project": mercenary epidemiology--data reanalysis and reinterpretation for sponsors with financial interest in the outcome.

Michaels D. Michaels D. Ann Epidemiol. 2006 Jul;16(7):583-5; author reply 586. doi: 10.1016/j.annepidem.2006.04.004. Ann Epidemiol. 2006. PMID: 16814150 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

103 results

Results by year